Gapping up
In reaction to strong earnings/guidance:MAGS +3.7%
M&A news: EXC +9.8% (Exelon and Pepco Holdings (POM) issue statement following PSCDC's Order, says continue to believe the merger proposal is in the public interest, and will continue working to complete the merger)
Other news: BLFS +60% (announced that its customer TiGenix recently disclosed that its lead compound Cx601 met the primary endpoint in the Phase III ADMIRE-CD trial ), RXII +21.5% (he 30-day review period following the filing of the Company's Investigational New Drug (IND) for ocular indications with the U.S. Food and Drug Administration (FDA) has passed and the IND is now active), MDCO +19.7% (positive ongoing Phase 1 clinical trial with ALN-PCSsc for the treatment of hypercholesterolemia), VTL +19.1% (presentation of additional data from its VTI-208 clinical trial), BVX +17% (FDA 510(k) Approval for New J-Plasma Pistol Grip Configurations), GDP +7.9% (suspends the quarterly dividends on some of its Convertible Preferred Stock), ICPT+5.3% (still checking), ALNY +4.5% (reports ALN-PCSsc generally well tolerated with no clinically significant drug-related adverse events to date), PSX +3.1% (Berkshire Hathaway late Friday disclosed an ~58 mln share, or ~$4.5 bln stake as of August 28th), QURE +1.7% (Point72 discloses an increased 5.0% passive stake in 13G filing)
Analyst comments: SUNE +5.8% (initiated with an Outperform at Macquarie), TWTR +3.4% (upgraded to Buy from Neutral at Sun Trust Rbsn Humphrey), JCP +2.6% (upgraded to Buy from Hold at Deutsche Bank
)
In reaction to strong earnings/guidance:MAGS +3.7%
M&A news: EXC +9.8% (Exelon and Pepco Holdings (POM) issue statement following PSCDC's Order, says continue to believe the merger proposal is in the public interest, and will continue working to complete the merger)
Other news: BLFS +60% (announced that its customer TiGenix recently disclosed that its lead compound Cx601 met the primary endpoint in the Phase III ADMIRE-CD trial ), RXII +21.5% (he 30-day review period following the filing of the Company's Investigational New Drug (IND) for ocular indications with the U.S. Food and Drug Administration (FDA) has passed and the IND is now active), MDCO +19.7% (positive ongoing Phase 1 clinical trial with ALN-PCSsc for the treatment of hypercholesterolemia), VTL +19.1% (presentation of additional data from its VTI-208 clinical trial), BVX +17% (FDA 510(k) Approval for New J-Plasma Pistol Grip Configurations), GDP +7.9% (suspends the quarterly dividends on some of its Convertible Preferred Stock), ICPT+5.3% (still checking), ALNY +4.5% (reports ALN-PCSsc generally well tolerated with no clinically significant drug-related adverse events to date), PSX +3.1% (Berkshire Hathaway late Friday disclosed an ~58 mln share, or ~$4.5 bln stake as of August 28th), QURE +1.7% (Point72 discloses an increased 5.0% passive stake in 13G filing)
Analyst comments: SUNE +5.8% (initiated with an Outperform at Macquarie), TWTR +3.4% (upgraded to Buy from Neutral at Sun Trust Rbsn Humphrey), JCP +2.6% (upgraded to Buy from Hold at Deutsche Bank
)